Learning from Other Tumors: Pathways for Progress and Overcoming Challenges in Cholangiocarcinoma

Cancers, Journal Year: 2025, Volume and Issue: 17(1), P. 156 - 156

Published: Jan. 6, 2025

Cholangiocarcinoma (CCA) is a group of complex and heterogeneous tumors originating from the epithelial cells bile ducts that can occur in intrahepatic, perihilar, or distal localizations [...]

Language: Английский

Precision medicine: an intrahepatic cholangiocarcinoma with a novel RBPMS-MET fusion sensitive to crizotinib

The Oncologist, Journal Year: 2024, Volume and Issue: 30(1)

Published: Dec. 10, 2024

Intrahepatic cholangiocarcinoma is a malignant tumor that starts from the epithelium of bile duct and has poor prognosis. They are characterized by response to chemotherapy lack effective targeted therapies; thus, therapeutic options limited. A 59-year-old man was admitted hospital for workup abnormal CA19-9 levels. He diagnosed with ICC, underwent surgery found have pT1bNx disease. developed rapid disease recurrence on adjuvant gemcitabine + capecitabine. Following recurrence, he received first-line systemic pembrolizumab lenvatinib second-line had mild regression followed progression. Next-generation sequencing performed baseline surgical sample. This revealed novel RBPMS-MET fusion, based literature, crizotinib 250 mg twice day administered. After 3 months treatment, magnetic resonance imaging significant reduction in liver lesions, 4 after initiating scans demonstrated partial response. Our case report strengthens evidence may be viable treatment option patients ICC c-MET tyrosine kinase necessitating additional clinical investigation.

Language: Английский

The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers

Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102955 - 102955

Published: May 1, 2025

Language: Английский